Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo

British Journal of Pharmacology

Volumn 167, Issue 4, 2012, Pages 881-891

  Ackler, S ^a   Mitten, M J ^a   Chen, J ^a   Clarin, J ^a   Foster, K ^a   Jin, S ^a   Phillips, D C ^a   Schlessinger, S ^a   Wang, B ^a   Leverson, J D ^a   Boghaert, E R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 263; Bcl 2; bendamustine; lymphoma; navitoclax

Indexed keywords

BENDAMUSTINE; CASPASE 3; NAVITOCLAX; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; HUMANS; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; NITROGEN MUSTARD COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866978330     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02048.x     Document Type: Article

References (38)

1. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al,. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7: 3265-3274.
2. Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al,. (2010). The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66: 869-880.
3. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al,. (2010). Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28: 3360-3365.
4. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, et al,. (2009). Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 113: 4038-4048.
5. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, et al,. (2002). Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87: 33-43.
6. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al,. (2009). Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114: 2721-2729.
7. Dyer MJ, Lillington DM, Bastard C, Tilly H, Lens D, Heward JM, et al,. (1996). Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus. Leukemia 10: 1198-1208.
8. Garnock-Jones KP, (2010). Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 70: 1703-1718.
9. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R, (2008). Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 134: 245-253.
10. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, et al,. (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 77: 483-494.
11. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al,. (eds) (2011). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute: Bethesda, MD.
12. Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, et al,. (2009). Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma 50: 1174-1182.
13. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, et al,. (2008). Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14: 5416-5425.
14. TM) enhances the tumor growth inhibitory effects of rituximab in Daudi lymphoma xenografts. Blood (ASH Annual Meeting Abstracts) 104: abstr 4580.
15. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al,. (2007). Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110: 2057-2066.
16. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP, (2008). Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580-595.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
18. Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, et al,. (2007). BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21: 1763-1772.
19. Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, et al,. (2007). Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 14: 1667-1677.
20. Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, et al,. (2008). ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140: 181-190.
21. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al,. (2008). Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14: 309-317.
22. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, et al,. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1181-1189.
23. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, et al,. (2009). The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23: 2034-2041.
24. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al,. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
26. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, et al,. (2008). The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112: 2906-2916.
27. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, et al,. (2008). Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51: 6902-6915.
28. Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P, Villamor N, Montserrat E, et al,. (2008). Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 14: 6907-6915.
29. Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, et al,. (2009). Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114: abstr 405.
30. Sekiguchi N, Kobayashi Y, Yokota Y, Kusumoto S, Tanimoto K, Watanabe T, et al,. (2005). Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis. Cancer Sci 96: 77-82.
31. L potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66: 8731-8739.
32. Stolz C, Hess G, Hahnel PS, Grabellus F, Hoffarth S, Schmid KW, et al,. (2008). Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 112: 3312-3321.
33. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S, (1996). Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7: 415-421.
34. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al,. (1982). Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79: 7837-7841.
35. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al,. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
36. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM, (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226: 1097-1099.
37. Wang Y, Castanar R, Bolos J, (2008). ABT-263. Drugs Fut 33: 829-837.
38. Wei MC, (2004). Bcl-2-related genes in lymphoid neoplasia. Int J Hematol 80: 205-209.